Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 16, 2026 | June 18, 2026 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | August 09, 2018 | August 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,629 |
Last balance in matching sequence
After 2026-06-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-06-16 · Exercise / conversion · Acquired 2,145 · Balance 35,774 F1: These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026. Row 2 · 2026-06-16 · Sale · Disposed 2,145 · Balance 33,629 F1: These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.13 · Expires 2027-05-25 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-16 · Exercise / conversion · Disposed 2,145 · Balance 0 F2: These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026.
F2: These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company.
NOVELION THERAPEUTICS INC.
Report date August 09, 2018 · Filed August 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2028-08-09 | Direct | 10,000 |
Reported balance
After 2018-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-09 · Grant · Acquired 10,000 · Balance 10,000 F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2: The option shall vest in twelve equal monthly installments, beginning one month after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
F2: The option shall vest in twelve equal monthly installments, beginning one month after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2017 Filed Dec 21, 2017 11:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 925 | $137.25 | $126,956.25 |
DisclosureSEC source: 0001104659-17-074431 · a4.xml · nonDerivative · entry 1 Sabba Stephen L · CIK 0001442372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,985 F1 · security: These securities, as represented in Column 5 and as previously reported in the Form 4 filed for this Reporting Person on May 30, 2017, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:02 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,456 | $0.00 Strike: $113.50 | $0.00 |
DisclosureSEC source: 0001104659-17-035988 · a4.xml · derivative · entry 2 Sabba Stephen L · CIK 0001442372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,456 Underlying: Common Stock · 2,456 shares Expires 2027-05-25 F2 · security: These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time. F2 · derivative.exercise_date: These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:02 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-035988 · a4.xml · nonDerivative · entry 1 Sabba Stephen L · CIK 0001442372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,910 F1 · security: These securities, as represented in Column 5, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 16:11 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001104659-16-163886 · a4.xml · derivative · entry 1 Sabba Stephen L · CIK 0001442372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Shares · 9,600 shares Expires 2026-12-22 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.